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Over ten years ago, C. auris was found for the first time in a Japanese patient’s ear canal. 
Today, the newly emerged pathogen is 
considered a leading cause of hospital-
acquired fungal infections and one of 
the most drug-resistant yeasts known 
to man. Currently, more than 90% of 
isolates are resistant to fluconazole – the 
primary antifungal used to treat Candida 
infections – and many exhibit resistance 
to more than one of the three major 
antifungal classes. As a result,  
C. auris is difficult to treat and eradicate 
from intensive care units. Indeed, 
bloodstream infections have mortality 
rates of up to 50% and clinical alerts 
have been issued by US, EU and UK 
health authorities.
Despite its clinical significance, little 
is known about where the yeast came 
from or how it became capable of 
colonising and infecting humans. 
Researchers have yet to isolate C. auris 
outside a hospital, and the yeast has 
radiated from clinics in East Asia, South 
Asia, South Africa and South America 
to appear in the Middle East, Australia, 
North America, mainland Europe and 
the UK. Additionally, information on the 
fungus’ general biology and life cycle 
remains elusive, making the correct 
identification and treatment of the 
pathogen in clinics more difficult. 
Now, University of Aberdeen researcher 
Dr Alexander Lorenz and his team are 
studying C. auris to see how genetic 
diversity among isolates drives virulence 
and drug-resistance.
SHUFFLING THE 
(CHROMOSOMAL) DECK
Fungal pathogens such as Cryptococcus 
neoformans, Candida albicans and  
C. lusitaniae, a close relative of C. auris, 
often reconfigure their chromosomes 
to help them adapt to stressful 
environments. Apparently, C. auris does 
too. After testing 26 clinical isolates 
from the four geographic ‘epicentres’, 
Lorenz and his team discovered that 
even the most closely related strains 
had varying chromosome numbers, with 
East Asian strains having five to seven 
chromosomes and South Asian isolates 
having six or seven, despite sharing 
relatively uniform DNA sequences. The 
key to their disparity lies, at least partly, 
in the DNA’s stability – or rather, its 
instability. According to Lorenz, between 
one and four chromosomes harboured 
repeated copies of a gene called 
ribosomal DNA or rDNA which have 
proven volatile in other yeasts. In fact, 
these ‘rDNA repeats’ are often involved 
in gross chromosome rearrangements 
– leading to increased genetic diversity, 
altered gene expression and potential 
adaptations to challenging environments. 
Candida auris 
The path of yeast resistance
Antibiotic-resistant bacteria 
have gained a lot of attention 
in recent years, but there’s 
another budding ‘villain’ that 
demands a spotlight and it 
comes in the form of a yeast. 
Candida auris debuted on the 
public health scene in 2009 
after it was isolated from a 
Japanese patient’s ear canal. 
Since then, the multidrug-
resistant fungus has become a 
“major healthcare threat, with 
hospital outbreaks occurring 
worldwide”. Now, University 
of Aberdeen researcher  
Dr Alexander Lorenz and his 
team are working to find out 
how the pathogen is able to 
colonise and infect humans 
and discover the key to its 
antifungal resistance. 
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To see just how helpful these 
chromosome rearrangements can be, 
Lorenz and his team subjected four 
clinical strains (each from a different 
geographical hotspot) to heat, osmotic 
and genotoxic stress. To induce osmotic 
stress, the researchers exposed C. auris to 
a high concentration of the sugar sorbose. 
Osmotic stress is the sudden change in 
water movement across the cell wall (or 
cell membrane) caused by exposing cells 
to high concentrations of sugars or salts. 
Cells can adapt to this via stress response 
mechanisms. This process mimics the 
consequences of treating yeast with an 
echinocandin-type antifungal, which 
prevents cell wall synthesis. Meanwhile, 
genotoxic stress was achieved using a 
chemical that reduces the number of 
nucleotides available for DNA replication. 
Finally, heat stress was produced by 
growing the fungus at a sweltering 42°C.
In all cases, chromosomes appeared, 
disappeared or changed sizes, with 
frequency and type of alteration differing 
depending on the strain and condition 
used. However very few modifications 
– mainly those in East Asian and South 
American strains – actually resulted in 
improved growth. It’s worth noting, 
though, that they did not appear 
to hinder viability or growth either.
This is especially striking in the South 
African strain, which continued to grow 
after consolidating its genome from 
seven to three chromosomes when 
placed under heat stress. The yeast 
likely achieved this, either by tethering 
chromosomes from end-to-end or 
breaking its chromosomes apart and 
fusing the pieces to other chromosomes, 
according to the researchers. Such drastic 
changes could provide opportunities for 
adaptation rather than squander the cell 
viability of C. auris, the researchers added.
A SELECTION OF TRICKS
Chromosome shuffling isn’t the only 
adaptive trick up C. auris’ sleeve. The 
pathogenic yeast is studded with 
transporter proteins, capable of pumping 
antifungal drugs out of the cell. These 
proteins are more frequently expressed 
in the presence of antifungals such as 
azoles and polyenes, bolstering the 
yeast’s defences against the distressing 
compounds. 
Additionally, under certain genotoxic 
conditions, many C. auris strains are 
capable of forming filaments called 
pseudohyphae. While there is insufficient 
data to confirm the role of pseudohyphae 
in the virulence of C. auris, filamentous 
growth has been shown to play an 
important part in host-pathogen 
attachment and disease development 
in other fungi. Combined with the 
malleable and adaptable genome of 
C. auris, this ability could allow clinical 
isolates to harness filamentous growth 
during pathogenesis.
Since [2009], the multidrug-resistant 
fungus has become a ‘major healthcare 
threat, with hospital outbreaks  
occurring worldwide’.
Light (first on left) and fluorescence (three on right) microscopy images of C. auris. In the image on the far right, DNA (red) as in second picture 
from left, and the cell wall (blue) as in third picture from left are visible.
So far, little is known about how the yeast became capable of colonising 
and infecting humans on a global scale.
Electron microscopy image of C. auris.
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drug, however, the researchers used 
another fungus. When cultured together 
with C. auris, a predatory yeast, 
Saccharomycopsis schoenii, attacked 
and killed its cellmates using specialised 
lance-like structures. Within six hours, 
S. schoenii had eliminated 34% of C. 
auris, while almost no C. auris cells died 
when cultured on its own. Importantly, 
drug-resistant forms of C. auris were still 
susceptible to the predator. The results 
make S. schoenii a promising, if novel, 
candidate for biocontrol.
NEXT STEPS
In the 11 years since its discovery,  
C. auris has gained a reputation as 
one of the biggest causes of hospital-
acquired fungal infections and one of 
the most drug-resistant yeasts known 
to science. Despite its global prevalence 
and dangerous nature, little is known 
about where the fungus came from, 
how it came to infect humans or how it 
developed antifungal resistance. To  
help fill these knowledge gaps, Lorenz 
and his team have been studying  
C. auris – exploring its adaptability, 
genome structure, virulence factors and 
even ways to combat the fungus in clinics. 
Already, they’ve made considerable 
progress, but there’s still a lot left to learn 
about this mysterious organism, including 
its general biology, life cycle, additional 
contributors to its genome plasticity 
and how to defeat the yeast in patients.
Lorenz and his team have found a 
potential way to fight back – at least 
in the clinic. Instead of an antifungal 
RESEARCHERS SHOW THEIR HAND
While C. auris has shown itself to be a 
formidable and ‘mysterious’ organism, 
… even the most closely related strains 
had varying chromosome numbers … 
despite sharing relatively uniform  
DNA sequences.
In order to find out more about C. auris’ fitness, four clinical strains, each from a  
different geographical location, were subjected to heat, osmotic and genotoxic stress.
Candida infections used to be treated with 
fluconazole, but now more than 90% of isolates 
are resistant to the antifungal medication.
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Personal Response
What prompted you to study C. auris?
 My main reason was being curious about the weird 
and wonderful life cycles of (pathogenic) fungi. I moved 
to Aberdeen in 2013 with a view to collaborate with 
researchers at the Aberdeen Fungal Group on a project 
with a pathogenic fungus. Professor Neil Gow then 
suggested that studying the life cycle of C. auris would 
be a worthwhile endeavour, because it is clinically 
relevant, and we know so little about it.  
Do you plan to continue studying the yeast, and if 
so, have you got any ideas for your next project? 
 My lab is working hard to develop molecular cell 
biology tools and genetic manipulation techniques 
for C. auris to do more in-depth experiments. Using 
genomics, we continue to study the strain with only 
three chromosomes to learn how C. auris rearranges 
its chromosomes during stress response. 
Dr Lorenz’s work investigates how genetic diversity is 
generated in Candida auris, and how this drives the 
evolution of antifungal resistance. 
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